Emmanuelle

Key Charpentier/Doudna CRISPR Patent Upheld by China National Intellectual Property Administration

Retrieved on: 
Tuesday, March 26, 2024
Research, Legal, Medical Devices, Patent Law, Genetics, Professional Services, Biotechnology, Pharmaceutical, Health, Science, Trade, CVC, Patent, RNA, CNIPA, Emmanuelle, University, Genomics, CRISPR, Eukaryote, Intellectual property, Cas9

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge.

Key Points: 
  • ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge.
  • The decision to uphold the patent right in China follows a recent decision by the Japanese Patent Office earlier this year to uphold JP6692856, also part of the CVC portfolio1.
  • The decision by the CNIPA, fully upholding the patent, further demonstrates its validity and value as part of the patent collection for use of the CRISPR/Cas9 technology.
  • Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics, said: “The decision by the CNIPA is testament to the strength of the foundational CVC CRISPR/Cas9 patent portfolio.

Buckle Up for Hilarious Ride as Kevin Sorbo, Barry Bostwick, Jon Lovitz and Emmanuelle Vaugier Star in New Comedy 'Potwins' TV Show on X Platform

Retrieved on: 
Tuesday, February 6, 2024
Emmanuelle, Humour, Entertainment

NAPLES, Fla., Feb. 6, 2024 /PRNewswire/ -- Prepare for a comedy series like no other as esteemed actors Kevin Sorbo, Barry Bostwick, Jon Lovitz and Emmanuelle Vaugier come together to headline an exciting new comedy TV show set to debut on the X platform (formally Twitter).

Key Points: 
  • NAPLES, Fla., Feb. 6, 2024 /PRNewswire/ -- Prepare for a comedy series like no other as esteemed actors Kevin Sorbo, Barry Bostwick, Jon Lovitz and Emmanuelle Vaugier come together to headline an exciting new comedy TV show set to debut on the X platform (formally Twitter).
  • "Potwins" is not your typical family comedy, it's topical, edgy and unafraid to dive into controversial subject matters.
  • Bradford Broyles, the producer behind the Potwins, chose X platform due to its massive 90 million American audience members and unwavering dedication to free speech.
  • "X provides the perfect stage for Potwins to reach a wide audience and push the boundaries of comedy.

ERS Genomics and StemSight Sign CRISPR/Cas9 License Agreement

Retrieved on: 
Wednesday, January 17, 2024
Health, Stem Cells, Other Science, Research, Science, Optical, Biotechnology, Family, Patient, Regenerative medicine, Emmanuelle, CRISPR, Partnership, Genomics, Tissue engineering, Tampere University, Cas9, Opacity (optics), B cell, Pharmaceutical industry

ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and StemSight Oy (‘StemSight’), a biotechnology company developing stem cell based therapies for corneal blindness, today announced a non-exclusive CRISPR/Cas9 license agreement.

Key Points: 
  • ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and StemSight Oy (‘StemSight’), a biotechnology company developing stem cell based therapies for corneal blindness, today announced a non-exclusive CRISPR/Cas9 license agreement.
  • The agreement grants StemSight access to ERS’ CRISPR/Cas9 patent portfolio.
  • Dr Laura Koivusalo, CEO and Co-founder of StemSight, said: “This partnership with ERS Genomics is a significant leap forward for StemSight.
  • With 89 patents held in over 90 countries, ERS Genomics licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide.

Key Charpentier/Doudna CRISPR patent upheld by Japanese Patent Office

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Genetics, Health, Clinical Trials, Trade, Intellectual property, JPO, Genomics, Emmanuelle, University, Cas9, CRISPR, CVC, Patent, Pharmaceutical industry, Television

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its second Japanese Patent (JP6692856) was upheld for the second time, in response to an invalidation challenge.

Key Points: 
  • ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its second Japanese Patent (JP6692856) was upheld for the second time, in response to an invalidation challenge.
  • The patent, filed by Dr. Charpentier, together with The Regents of the University of California and University of Vienna (collectively known as CVC), was also upheld previously by the Japanese Patent Office (JPO) in 20211.
  • During the proceedings, novelty and inventive step were contested.
  • In the decision2, the JPO rejected both challenges to patentability, fully upholding the patent and further demonstrating its validity and value as part of the patent collection for use of the CRISPR/Cas9 technology.

Foundational CRISPR/Cas9 gene editing patent granted to CVC in Canada

Retrieved on: 
Thursday, January 5, 2023
ERS, Nobel, Agriculture, Corporate development, University of Vienna, Gene editing, Plant, DNA, CVC, Food, Genomics, Intellectual property, Animal, Emmanuelle, CRISPR, Paganini Competition, University, Nobel Prize, UC, Patent, Human, History, University of California, Berkeley, University of California, Cell, Pharmaceutical industry, Vaccine, Cas9, DRS

ERS, co-founded by Nobel Laureate Dr. Emmanuelle Charpentier, provides access to a broad portfolio of over 80 foundational CRISPR/Cas9 patents worldwide.

Key Points: 
  • ERS, co-founded by Nobel Laureate Dr. Emmanuelle Charpentier, provides access to a broad portfolio of over 80 foundational CRISPR/Cas9 patents worldwide.
  • Canada has an impressive history in the life science arena and we foresee CRISPR playing an important role in the future of Canadian biotech.
  • Not only in the human therapeutic arena, but in other applications impacting animal health, food and agriculture, and environmental issues.'
  • Emmanuelle Charpentier and Jennifer Doudna, ERS has put in place over 100 licenses to a growing list of issued and pending patent applications globally.

Foundational CRISPR/Cas9 gene editing patent granted to CVC in Canada

Retrieved on: 
Thursday, January 5, 2023
ERS, Nobel, Agriculture, Corporate development, University of Vienna, Gene editing, Plant, DNA, CVC, Food, Genomics, Intellectual property, Animal, Emmanuelle, CRISPR, Paganini Competition, University, Nobel Prize, UC, Patent, Human, History, University of California, Berkeley, University of California, Cell, Pharmaceutical industry, Vaccine, Cas9, DRS

ERS, co-founded by Nobel Laureate Dr. Emmanuelle Charpentier, provides access to a broad portfolio of over 80 foundational CRISPR/Cas9 patents worldwide.

Key Points: 
  • ERS, co-founded by Nobel Laureate Dr. Emmanuelle Charpentier, provides access to a broad portfolio of over 80 foundational CRISPR/Cas9 patents worldwide.
  • Canada has an impressive history in the life science arena and we foresee CRISPR playing an important role in the future of Canadian biotech.
  • Not only in the human therapeutic arena, but in other applications impacting animal health, food and agriculture, and environmental issues.'
  • Emmanuelle Charpentier and Jennifer Doudna, ERS has put in place over 100 licenses to a growing list of issued and pending patent applications globally.

Patent upheld, ERS leadership position in European CRISPR Landscape confirmed

Retrieved on: 
Tuesday, May 31, 2022
Eukaryote, B cell, European Patent Office, Nobel Prize, EPO, Plant, VP, GMP, Enzyme, Cas9, Confusion, Multimedia, View, Synthetic biology, Biofuel, CVC, Intellectual property, Emmanuelle, Research, Patent, OD, EP400, CRISPR, Human, Opposition procedure before the European Patent Office, Technology, Genomics, University, Sale, Animal, ERS, European Patent Convention, Moore v. Regents of the University of California, CEO, Pharmaceutical industry

DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.

Key Points: 
  • DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.
  • European Patent 3401400 ('EP400') has withstood formal opposition at the European Patent Office ('EPO') with only minor modifications.The decision by the EPO Opposition Division ('OD') was recently published following lengthy hearings which concluded in February of this year.
  • The patent is jointly owned by ERS founder and Nobel prize winner Dr. Emmanuelle Charpentier, along with the University of Vienna and the University of California (jointly known as the 'CVC' group).
  • Opponents had challenged EP400 at the European Patent Office formally claiming lack of novelty and inventive step and asking the OD to revoke the patent in its entirety.

Patent upheld, ERS leadership position in European CRISPR Landscape confirmed

Retrieved on: 
Tuesday, May 31, 2022
Eukaryote, B cell, European Patent Office, Nobel Prize, EPO, Plant, VP, GMP, Enzyme, Cas9, Confusion, Synthetic biology, Biofuel, CVC, Intellectual property, Emmanuelle, Research, Patent, OD, EP400, CRISPR, Human, Opposition procedure before the European Patent Office, Technology, Genomics, University, Sale, Animal, ERS, European Patent Convention, Moore v. Regents of the University of California, CEO, Pharmaceutical industry

DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.

Key Points: 
  • DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.
  • European Patent 3401400 ('EP400') has withstood formal opposition at the European Patent Office ('EPO') with only minor modifications.The decision by the EPO Opposition Division ('OD') was recently published following lengthy hearings which concluded in February of this year.
  • The patent is jointly owned by ERS founder and Nobel prize winner Dr. Emmanuelle Charpentier, along with the University of Vienna and the University of California (jointly known as the 'CVC' group).
  • Opponents had challenged EP400 at the European Patent Office formally claiming lack of novelty and inventive step and asking the OD to revoke the patent in its entirety.

Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

Retrieved on: 
Monday, February 28, 2022
GLOBE, Cell, Patent, Editas Medicine, United States Court of Appeals for the Federal Circuit, Security (finance), CRISPR, Annual report, Genome, Company, Eukaryote, Clinical trial, USPTO, U.S. Securities and Exchange Commission, U.S. Patent No. 1, CVC, DNA, Private Securities Litigation Reform Act, Nasdaq, Emmanuelle, Technology, Cas9, University of California, University of Vienna, Gene editing, Vaccine, Pharmaceutical industry

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leadinggenome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued another favorable decision to theBroad Institute, Inc.(Broad) involving specific patents for CRISPR/Cas9 editing in human cells.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leadinggenome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued another favorable decision to theBroad Institute, Inc.(Broad) involving specific patents for CRISPR/Cas9 editing in human cells.
  • Pending an appeal to the Federal Circuit, this decision ends the U.S. patent interference between theUniversity of California, theUniversity of Vienna, and Emmanuelle Charpentier (collectively, CVC)and Broad.
  • The patents at issue in the current interference are owned by Broad and exclusively licensed to Editas Medicine for the development of medicines for people living with serious diseases.
  • Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.

CVC maintains strong US patent portfolio covering CRISPR/Cas9 despite PTAB ruling, reports ERS Genomics

Retrieved on: 
Tuesday, March 1, 2022
Intellectual property, GMP, Patent, Method, Trade, CRISPR, University, Genomics, Eukaryote, Sale, Biofuel, Broad Institute, RNA vaccine, CVC, Emmanuelle, Enzyme, Synthetic biology, Patent Trial and Appeal Board, PTAB, University of California, Riverside Citrus Variety Collection, Cas9, CEO, Research, Pharmaceutical industry, Rolling (metalworking), EU

CVC retains its patent rights in over 40 issued US patents that were never involved in this interference.

Key Points: 
  • CVC retains its patent rights in over 40 issued US patents that were never involved in this interference.
  • These patents cover a variety of compositions and methods for CRISPR/Cas9 gene editing, including dual-guide and single-guide formats.
  • In addition to its substantial portfolio of granted CRISPR/Cas9 patents in the US, CVC maintains fundamental CRISPR/Cas9 patents in over 80 countries including the EU, China, Japan and elsewhere.
  • Eric Rhodes, CEO of ERS Genomics said; "We remain convinced that the compositions, methods and techniques in the CVC portfolio of patents are the essential intellectual property for the practice of CRISPR/Cas9 gene editing."